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Abstract Recent findings demonstrate that accelerated
carcinogenesis following liver regeneration is associated
with chronic inflammation-induced double-strand DNA
breaks in cells, which escaped apoptosis due to prolifera-
tive stress. In this work, proliferative stress and inflam-
mation-based carcinogenesis at large dose were included in
a cancer induction model considering fractionation. At
large dose, tissue injury due to irradiation could be so
severe that under the regenerative proliferative stress
induced by cell loss, the genomic unstable cells generated
during irradiation and/or inflammation escape senescence
or apoptosis and reenter the cell cycle, triggering enhanced
carcinogenesis. This acceleration—modeled to be propor-
tional to the number of repopulated cells—is only signifi-
cant, however, when tissue injury is severe and thus
proportional to the cell loss in the tissue. The general
solutions to the resulting differential equations for carci-
noma induction were computed. In case of full repopula-
tion or acute low-dose irradiation, the acceleration term
disappears from the equation describing cancer induction.
The acceleration term is affecting the dose–response curve
for carcinogenesis only at large doses. An example for
bladder cancer is shown. An existing model for cancer
induction after fractionated radiotherapy which is based on
cell mutations was extended here by including the effects
of inflammation and proliferative stress, and an additional
model parameter was established which describes accel-
eration. The new acceleration parameter affects the dose–
response model only at large dose and is only effective
when the tissue is not capable of fully repopulating
between dose fractions.
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Introduction
Over the past three decades, advances in cancer treatment
have steadily improved survival times. As a consequence,
among all cancer survivors in 2001, 14 % had received a
cancer diagnosis more than 20 years ago (Rowland et al.
2004). Approximately half of these long-term survivors
received a radiotherapy treatment and are thus subject to
radiation-related side effects. These long-term survivors
experience a significant incidence of chronic health prob-
lems after their treatment, including second primary cancer
(Suit et al. 2007).
Research and development in radiation oncology is
mainly directed to further increase the cure rates. This is
currently achieved by application of new radiation treat-
ment modalities such as intensity-modulated radiotherapy
(IMRT), intensity-modulated arc-therapy and proton and
heavy-ion radiotherapy. Note, however, that the long-term
risks from modern radiotherapy treatment techniques have
not yet been determined and are unlikely to become
apparent for many years, due to the long latency time for
solid tumor induction. Therefore, decisions on potential
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risk induction must be made using theoretical predictions
(Newhauser and Durante 2011) including the development
of models for risk assessment based on the current
knowledge of radiation-induced carcinogenesis.
Several models for risk assessment have been proposed.
Since dose fractionation is common in radiation therapy
and can be important for carcinogenesis, it was included in
recent models by considering cell repopulation between the
dose fractions (Sachs and Brenner 2005; Shuryak et al.
2009a; Shuryak et al. 2009b; Pfaffenberger et al. 2009;
Schneider 2009; Schneider et al. 2011). Repopulation tends
to counteract cell killing and accounts for large discrep-
ancies between the standard model for cancer induction
neglecting fractionation at high doses (‘‘bell-shaped
model’’) and recent second cancer data (Hall 2000).
Practically, all models describe carcinogenesis induced
by ionizing radiation as a (multi-)mutational process in the
cells. This approach to cancer induction might work well at
low doses. At large doses ([20 Gy), however, also cell
sterilization effects can play an important role. Sterilization
of a large number of cells could lead, for example, to
inflammations (Philip et al. 2004) or proliferative stress
(Barash et al. 2010), which additionally could initiate
carcinogenesis. Thus, cancer induction at large dose could
be systematically underestimated by current models.
The aim of the present study was to include the mech-
anisms of proliferative stress and inflammation-based car-
cinogenesis at large dose into a cancer induction model
including fractionation. This was accomplished by apply-
ing recent results of Barash et al. (2010), who found that
accelerated carcinogenesis following liver regeneration is
associated with chronic inflammation-induced double-
strand DNA breaks in cells that escaped apoptosis due to
proliferative stress.
Materials and methods
Accelerated carcinogenesis following organ
regeneration
Barash et al. (2010) reported in a recent publication that liver
resection significantly promotes carcinogenesis and attenuates
regeneration. They proposed that under the regenerative pro-
liferative stress induced by liver resection, the genomic unsta-
ble hepatocytes generated during chronic inflammation escape
senescence or apoptosis and reenter the cell cycle, triggering the
enhanced carcinogenesis. In their study Mdr2-KO mice, a
model of inflammation-associated cancer, underwent partial
hepatectomy, which led to enhanced hepatocarcinogenesis.
Barash et al. (2010) clarified the immediate and long-term
contributions of the DNA damage response to hepatocellular
carcinoma development and recurrence.
In the present work, it is proposed that this mechanism
also plays a role in radiotherapy where large doses of
ionizing radiation affect healthy organs adjacent to the
target volume. Inaccurate DNA repair can lead to muta-
tions and/or chromosomal aberrations that can contribute to
carcinogenesis (Bartkova et al. 2005; Van Gent et al.
2001). Proliferative stress during radiotherapy is triggered
by the sterilization of large parts of an organ by radiation
and the following regeneration of the lost cells (Do¨rr and
Kummermehr 1990). Some of the cells created during
regeneration are genomic unstable, due to radiation-
induced DNA damage or inflammatory processes (as a
consequence of high-dose radiation therapy). Some of
these genomic unstable cells may escape senescence and
apoptosis under the regenerative proliferative stress, reen-
ter the cell cycle and thus trigger enhanced carcinogenesis.
This mechanism is drafted in Fig. 1.
Mathematical formulation of accelerated
carcinogenesis following organ regeneration
In the following a model is developed which is close to a
mechanistic model for predicting cancer induction after
fractionated radiotherapy (Schneider 2009). Cell kill is
described by a linear-quadratic dose–response model,
while cancer induction is, for each dose fraction, modeled
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Fig. 1 a Situation at low-dose ionizing radiation where inflammatory
processes are negligible; ionizing radiation is inducing double-strand
breaks; however, apoptosis, cell cycle arrest and DNA repair are
actively eliminating mutated cells. b Large dose of ionizing radiation
is responsible for massive tissue injury, triggering enhanced cell
proliferation; the cells generated during irradiation and inflammation
may escape senescence and apoptosis and reenter the cell cycle, thus
triggering enhanced carcinogenesis
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linearly with dose, and between the dose fractions, repop-
ulation is allowed.
It is assumed that the tissue or organ of interest consists
of N0 cells before it is irradiated. At this stage there is no
distinction between cells that represent a particular func-
tion and do not divide, and stem cells that are dividing. The
tissue is then irradiated with a fractionated treatment
schedule of equal-dose fractions df up to a dose D. It is
important to note here that the single-dose fraction df
should not exceed a dose where the linear-no-threshold
hypothesis is no more valid, that is, df should be lower than
2 or 3 Gy.
The number of original cells after irradiation is reduced
by cell kill. A number of N cells survive one-dose fraction
(Eq. 1).
dNðDÞ
dD
¼ a0NðDÞ; ð1Þ
where the cell kill parameter a0 is for fractionated treatment
taken as
a0 ¼ aþ bdf ð2Þ
where a and b are the usual parameters from the linear-
quadratic model for the tissues of interest.
It is further assumed that the number of killed original
tissue cells N0 - N is replaced by a number of new cells
R with a repopulation rate that is proportional to cell loss
N0 - N - R. This is modeled by:
dRðDÞ
dD
¼ a0RðDÞ þ a0 r
1  r N0  NðDÞ  RðDÞð Þ;
8r 2 0; 1 ½ ð3Þ
where the parameter r is chosen such that it is proportional
to the ability of the tissue to repopulate; this parameter
varies between 0 for no and 1 for full repopulation between
single-dose fractions.
Here, it is assumed that the repopulation kinetics of
repopulated cells follows the same basic patterns as that of
normal cells.
Cells that were irradiated can be mutated and have the
potential to develop a tumor. In the context of the present
work, the word ‘‘mutation’’ is used as a synonym for each
cell transformation, which results in a new tumor cell. In
fact, the development of a tumor usually implies several
mutations. The mutational process is modeled to be pro-
portional to the number of cells (N ? R) present at the time
of irradiation. The proportionality constant is l.
At large dose, tissue injury due to irradiation could be so
severe that under the regenerative proliferative stress induced
by cell loss, the genomic unstable cells generated during
irradiation and/or inflammation may escape senescence or
apoptosis and reenter the cell cycle, triggering enhanced
carcinogenesis. This acceleration must be proportional (q) to
the number of repopulated cells R. However, acceleration is
only significant when tissue injury is severe and thus pro-
portional to (1 - (N - R)/N0), which characterizes the
amplitude of tissue injury. The differential equation
describing carcinoma induction is then:
dMCðDÞ
dD
¼ a0MCðDÞ þ lðNðDÞ þ RðDÞÞ
þ qRðDÞ 1  NðDÞ  RðDÞ
N0
 
ð4Þ
where MC is the number of mutated cells that lead to car-
cinoma induction. It is assumed here that the same cell kill
parameter a0 applies to normal, repopulated and mutated
cells. For carcinoma induction, it is further assumed that
the original tissue before irradiation consists, among oth-
ers, of dividing cells, and therefore, the induction rate is
proportional to the sum of the number of surviving original
and repopulated cells.
Cancer risk in this simple model is defined as the ratio of
the number of mutated cells to the number of original cells in
the tissue. This was done since we believe that an observed
cancer rate in an organ should be more or less independent of
the organ’s volume or mass. This hypothesis is supported by
the fact that various cell sterilization mechanisms are cell-
specific (i.e., apoptosis, senescence) or also scale with organ
size (i.e., the power of the immune system).
Results
Equations 1, 3 and 4 are first-order non-homogeneous
linear differential equations that can be solved analytically
using the initial conditions that the number of original cells
N(0) before treatment is N0 and the number of repopulating
cells R(0) and mutated cells Mc(0) is zero before the onset
of radiation. The problem is then solved by
NðDÞ ¼ N0ea0D ð5Þ
RðDÞ ¼ N0 r þ ð1  rÞe aDr1  ea0D
n o
ð6Þ
MCðDÞ ¼ N0e
a0D
a0rðr þ 1Þ qr r  1ð Þ
3e
a0D rþ1ð Þ
r1ð Þ

 r þ 1ð Þ r  1ð Þ2 lþ q 2qrð Þe a
0rD
r1ð Þ
qr r þ 1ð Þ r  1ð Þ2e a
0D
r1ð Þ þ r2 r þ 1ð Þ
 lþ q qrð Þea0D þ qr4 þ qr3ða0D  1Þ
þ2r2ðq lÞ  rðlþ 3qþ qa0DÞ þ lþ q

;
8r 2 0; 1 ½ ð7Þ
As described above, excess absolute risk (EAR) is then
simply Mc/N0.
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Due to the findings of Barash et al. (2010), the induction
of liver cancer is one example where accelerated carcino-
genesis could be of importance. We hypothesize that this
model can also be of importance for other locations. A
typical clinical example is bladder cancer, which can be a
side effect of treating prostate patients with high dose of
radiation. Since the bladder is located close to the target
volume (prostate), it can receive dose in the order of
70 Gy. At such large doses, tissue injury and cell loss due
to irradiation could be so severe that the genomic unstable
cells generated during irradiation may escape senescence
or apoptosis and trigger enhanced carcinogenesis. An
evidence that acceleration might be important for
the induction of bladder cancer is the fact that a bladder
dose–response model that was fitted to low-dose data
(DBladder \ 15 Gy) from Hodgkin’s patients (Schneider
and Walsh 2008; Schneider et al. 2011) is underestimating
risk when applied to patients who were treated for pros-
tate carcinoma (50 Gy \ DBladder \ 70 Gy). The dose–
response relationship for bladder cancer which was fitted to
Hodgkin’s patients is plotted as the solid line in Fig. 2.
The corresponding fitting parameters were l = 3.8/10,000
PY/Gy, a = 0.219/Gy, R = 0.09 and q = 0/10,000 PY/Gy,
respectively (Schneider et al. 2011). If this is applied to
dose distributions from historical prostate radiotherapy
treatments, an EAR of 3 cases per 10,000 PY is obtained.
This is in contradiction to epidemiological studies (Brenner
et al. 2000) where 9 cases per 10,000 PY were found. If an
acceleration parameter of q = 8/10,000 PY/Gy is used in
Eq. 7, which is shown as the dotted line in Fig. 2, then the
epidemiological findings can be reproduced.
In Fig. 3 the acceleration is shown as a function of the
repopulation factor for four different q values for liver
cancer. Acceleration is here defined as the maximum ratio
of EAR including acceleration to EAR without accelera-
tion, for a dose range up to 50 Gy.
Discussion
Equation 3 describes the repopulation rate for tissues that
correspond to a repopulation strength between no and full
repopulation (0 \ r \ 1). One question is what is hap-
pening for zero and full repopulation.
If there is no repopulation in the tissue, there are no
repopulated cells, and thus, R(d) is always zero. If we use
R(d) = 0, then from Eq. 4 it follows
MCðD; r ! 0Þ ¼ lN0Dea0D: ð8Þ
In this limit, cancer risk is solely proportional to l and
independent of q, which is consistent with the assumption
that for acute exposures carcinogenesis is triggered mainly
by mutational processes. If Eq. 8 is taken in the limit of
small dose (i.e., for a0D  1), our model is in perfect
agreement with the linear-no-threshold model if excess
absolute cancer risk is expressed by Mc/N0:
EARCðD; r ! 0Þ ¼ MCðD; r ! 0Þ
N0
 lD  ð1  a0DÞ
 lD for a0D  1 ð9Þ
Hence, in Eq. 7 the parameter l represents the initial slope
at low dose and may be obtained directly from the analysis
of the A-bomb survivors (Preston et al. 2007; Schneider
et al. 2011). Usually, when Eq. 7 is fitted, a variation of the
parameter l is allowed in the 95 % confidence interval of
the A-bomb survivor data.
Fig. 2 Dose–response relationship for bladder cancer as a function of
point dose in the organ. The solid line represents a fit to Hodgkin’s
data with bladder doses lower than 15 Gy, obtained by a model
without acceleration. In contrast, the dotted line represents the dose–
response relationship including acceleration as calculated in this work
Fig. 3 Acceleration for liver cancer as a function of the repopulation
factor, for four different q values. Acceleration is here defined as the
maximum ratio of EAR including acceleration to that without
acceleration for a dose range up to 50 Gy
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In case of full repopulation (r = 1) between dose frac-
tions, Eq. 3 is redundant, since the number of repopulated
cells is simply
RðDÞ ¼ N0  N ¼ N0 1  ea0D
 
ð10Þ
When Eqs. 1, 10 and 4 are solved, EAR for carcinoma
induction is:
EARCðD; r ! 1Þ ¼ lCa0 1  e
a0D
 
; ð11Þ
In case of full repopulation, sterilized cells are fully
replaced after each fraction, and thus, no proliferative
stress can occur. As a consequence, EAR is independent of
q. This is also shown in Fig. 3 where the accelerated car-
cinogenesis is, independent of the parameter q, negligible
at full repopulation between the dose fractions, and the
value of the acceleration becomes unity. However, repop-
ulation power decreases as acceleration becomes more
important, since some of the cells created during repopu-
lation are genomic unstable (due to proliferative stress) and
can escape senescence and apoptosis.
It should be noted here that in addition to the limitations
of the model without acceleration, which is in detail dis-
cussed by Schneider (2009), the acceleration introduced in
the present study was modeled solely as a function of dose
during treatment, and thus, time-related effects indepen-
dent of dose such as the delayed start of repopulation (Do¨rr
and Kummermehr 1990) were completely neglected.
Note that proliferative stress might be only one mech-
anism that can lead to accelerated mutagenesis. Contribu-
tions to further mutagenesis might include enhanced tissue
hypoxia developing years after irradiation because of late
vascular effects.
One important question is for which organs the model
can be applied. Proliferative stress is important when the
repopulation power of the tissue is small (see Fig. 3). In a
recent publication (Schneider et al. 2011) the model
without acceleration was fitted to second cancer data, and
the parameter r was obtained. Organs that correspond to
r smaller than 0.3 comprise female breast, small intestine,
liver, bladder and salivary gland.
Conclusion
In the present study, an existing model for cancer induction
after fractionated radiotherapy which is based on cell
mutations was extended by including the effects of
inflammation and proliferative stress. It is proposed that
tissue injury due to high doses of radiation may be due to
enhanced cell proliferation. The cells generated during
irradiation and inflammation can escape senescence and
apoptosis and reenter the cell cycle, thus triggering an
enhanced carcinogenesis. An additional model parameter q
was introduced into the model to describe this acceleration.
The new acceleration parameter affects the dose–response
model only at large dose and is only effective when the
tissue is not capable of fully repopulating between dose
fractions.
The repopulation power of the different tissues suggests
that acceleration might be important for female breast, small
intestine, liver, bladder and salivary gland. However, more
research work is necessary to analyze the impact of accel-
erated carcinogenesis for radiotherapy patients. In particular,
detailed observations of second cancer induction rates after
radiotherapy at different dose levels are necessary.
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